Artificial intelligence, machine learning models, automation, connected devices, cloud data storage, intuitive study ...

Preliminary results from TROPION-Lung05 reported at the main ESMO congress last year revealed an overall response rate (ORR) ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

American College of Rheumatology (ACR) annual meeting spotlighted transformative advancements in cell therapies for ...

At ASCO, the stellar PFS data sparked speculation that Tagrisso will become the standard of care in this type of early lung ...

Quality compliance in the pharma industry is foundational to guaranteeing safe and effective products. For years, Good ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

This year was a year of significant new beginnings for pharma and healthcare, yet, it was still impacted by the long-term fallouts of the pandemic. 2024 will inherit the challenges of 2023 and see ...

Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a patient’s ...

pharmaphorum is your source for news and analysis to stay on top of happenings in the world of pharma. Founded in 2009, pharmaphorum’s mission has always been to educate, inform, engage, and ...